Robert H. Mak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert H. Mak has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Wai Cheung
6 shared publicationsHuey-Ju Kuo
Division of Pediatric Nephrology, Oregon Health & Science University, Portland, OR
3 shared publicationsDaniel L. Marks
Department of Pediatrics and 2Vollum Institute, Oregon Health and Science University, Portland, Oregon, USA
2 shared publicationsRoger D. Cone
Department of Pediatrics and 2Vollum Institute, Oregon Health and Science University, Portland, Oregon, USA
2 shared publicationsBrian M. Little
Department of Pediatrics and 2Vollum Institute, Oregon Health and Science University, Portland, Oregon, USA
1 shared publicationD.L. Marks
Department of Pediatrics, Oregon Health and Science University, Portland, Oregon, USA
1 shared publication
Latest Publications
- 1 October 2007
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (10) , 1687-1688
Chronic kidney disease in children: state of the art
- 1 October 2007
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (10) , 1687-1688
Chronic kidney disease in children: state of the art
- Open Access
- 1 January 2007
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 27 (1) , 51-55
Ghrelin in Chronic Kidney Disease: Too Much or Too Little?
- 1 January 2007
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 27 (1) , 51-55
Open AccessGhrelin in Chronic Kidney Disease: Too Much or Too Little?
- 1 January 2007
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (1) , 24-25
Teaching articles: a new goal of the journal
- 1 January 2007
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (1) , 24-25
Teaching articles: a new goal of the journal
- 1 January 2007
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 16 (1) , 27-31
Cachexia in chronic kidney disease: role of inflammation and neuropeptide signaling
This review will update clinicians and basic scientists who are interested in the clinical relevance and molecular mechanism of uremic cachexia. Recent studies that examine the role of cytokines and hypothalamic neuropeptides are emphasized. A current hypothesis of the cause of cachexia in chronic illness is that proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-6, and leptin, act on the central nervous system to alter the release and function of several key neurotransmitters, thereby altering both appetite and metabolic rate. Proinflammatory cytokines also activate the transcription factor nuclear factor-kappaB, resulting in decreased protein synthesis, and activate the ubiquitin-mediated proteolytic system, which is the major system involved in increased protein degradation. This review highlights the importance of melanocortin signaling in the pathogenesis of uremia-associated cachexia and the potential of peripheral administration of melanocortin-4 receptor antagonists as a novel therapeutic approach.
- 1 January 2007
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 16 (1) , 27-31
Cachexia in chronic kidney disease: role of inflammation and neuropeptide signaling
This review will update clinicians and basic scientists who are interested in the clinical relevance and molecular mechanism of uremic cachexia. Recent studies that examine the role of cytokines and hypothalamic neuropeptides are emphasized. A current hypothesis of the cause of cachexia in chronic illness is that proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-6, and leptin, act on the central nervous system to alter the release and function of several key neurotransmitters, thereby altering both appetite and metabolic rate. Proinflammatory cytokines also activate the transcription factor nuclear factor-kappaB, resulting in decreased protein synthesis, and activate the ubiquitin-mediated proteolytic system, which is the major system involved in increased protein degradation. This review highlights the importance of melanocortin signaling in the pathogenesis of uremia-associated cachexia and the potential of peripheral administration of melanocortin-4 receptor antagonists as a novel therapeutic approach.
- 1 December 2006
- Published by Springer Nature in Pediatric Nephrology
- Vol. 21 (12) , 1807-1814
Energy homeostasis and cachexia in chronic kidney disease
Loss of protein stores, presenting as clinical wasting, is reported to have a prevalence of 30–60% and is an important risk factor for mortality in chronic kidney disease (CKD) patients. There is debate as to whether the clinical wasting in CKD patients represents malnutrition or cachexia. Malnutrition results from inadequate intake of nutrients, despite a good appetite, and manifests as weight loss associated with adaptive metabolic responses such as decreased basic metabolic rate and preservation of lean body mass at the expense of fat mass. Furthermore, the abnormalities in malnutrition can usually be overcome simply by supplying more food or altering the composition of the diet. In contrast, cachexia is characterized by maladaptive responses such as anorexia, elevated basic metabolic rate, wasting of lean body tissue, and underutilization of fat tissue for energy. Diet supplementation and intradialytic parenteral nutrition have not been successful in reversing cachexia in CKD. The etiology of cachexia in CKD is complex and multifactorial. Two major factors causing muscle wasting in uremia are acidosis and decreased insulin responses. Inflammation secondary to cytokines may also play a significant role. The hypoalbuminemia of CKD patients is principally associated with inflammation and not changes in food intake. There is also recent evidence that hypothalamic neuropeptides may be important in the downstream signaling of cytokines in the pathogenesis of cachexia in CKD. Elevated circulating levels of cytokines, such as leptin, may be an important cause of uremia-associated cachexia via signaling through the central melanocortin system. Further research into the molecular pathways leading to cachexia may lead to novel therapeutic therapy for this devastating and potentially fatal complication of CKD.
- 1 December 2006
- Published by Springer Nature in Pediatric Nephrology
- Vol. 21 (12) , 1807-1814
Energy homeostasis and cachexia in chronic kidney disease
Loss of protein stores, presenting as clinical wasting, is reported to have a prevalence of 30–60% and is an important risk factor for mortality in chronic kidney disease (CKD) patients. There is debate as to whether the clinical wasting in CKD patients represents malnutrition or cachexia. Malnutrition results from inadequate intake of nutrients, despite a good appetite, and manifests as weight loss associated with adaptive metabolic responses such as decreased basic metabolic rate and preservation of lean body mass at the expense of fat mass. Furthermore, the abnormalities in malnutrition can usually be overcome simply by supplying more food or altering the composition of the diet. In contrast, cachexia is characterized by maladaptive responses such as anorexia, elevated basic metabolic rate, wasting of lean body tissue, and underutilization of fat tissue for energy. Diet supplementation and intradialytic parenteral nutrition have not been successful in reversing cachexia in CKD. The etiology of cachexia in CKD is complex and multifactorial. Two major factors causing muscle wasting in uremia are acidosis and decreased insulin responses. Inflammation secondary to cytokines may also play a significant role. The hypoalbuminemia of CKD patients is principally associated with inflammation and not changes in food intake. There is also recent evidence that hypothalamic neuropeptides may be important in the downstream signaling of cytokines in the pathogenesis of cachexia in CKD. Elevated circulating levels of cytokines, such as leptin, may be an important cause of uremia-associated cachexia via signaling through the central melanocortin system. Further research into the molecular pathways leading to cachexia may lead to novel therapeutic therapy for this devastating and potentially fatal complication of CKD.
- 1 November 2006
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 2 (11) , 608-609
Can plasma iohexol disappearance be used to measure GFR in children with chronic kidney disease?
- 1 November 2006
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 2 (11) , 608-609
Can plasma iohexol disappearance be used to measure GFR in children with chronic kidney disease?
- 31 October 2006
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 13 (4) , 374-385
Animal Models of Obesity-Associated Chronic Kidney Disease
- 31 October 2006
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 13 (4) , 374-385
Animal Models of Obesity-Associated Chronic Kidney Disease
- 1 September 2006
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 2 (9) , 527-534
Mechanisms of Disease: cytokine and adipokine signaling in uremic cachexia
Clinical wasting is an important risk factor for mortality in uremic patients and is reported to have a prevalence of 30-60%. 'Malnutrition' is often inappropriately used to describe a group of nutritional abnormalities in uremic patients, which are characterized by anorexia, increased basal metabolic rate, loss of lean body mass, and declining levels of serum proteins. This syndrome--more accurately described as 'cachexia'--manifests as growth failure in children with uremia. Acidosis and inflammation are important causes of uremic cachexia but the underlying molecular mechanism is not well understood. Concentrations of circulating cytokines, such as leptin, tumor necrosis factor-alpha, interleukin-1, and interleukin-6, are elevated in patients with end-stage renal disease and correlate with the degree of cachexia in these individuals. Other energy-modulating hormones such as ghrelin, and adipokines such as adiponectin and resistin, are also perturbed in uremia and could contribute to nutritional abnormalities. We recently showed that elevated levels of circulating cytokines might be an important contributor to uremia-associated cachexia via signaling through the central melanocortin system. Small-molecule melanocortin antagonists, which are biologically active when administered orally or intraperitoneally, are now available and have been used successfully to ameliorate experimental cachexia. These findings could form the basis of a novel therapeutic strategy for uremic cachexia.
- 1 September 2006
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 2 (9) , 527-534
Mechanisms of Disease: cytokine and adipokine signaling in uremic cachexia
Clinical wasting is an important risk factor for mortality in uremic patients and is reported to have a prevalence of 30-60%. 'Malnutrition' is often inappropriately used to describe a group of nutritional abnormalities in uremic patients, which are characterized by anorexia, increased basal metabolic rate, loss of lean body mass, and declining levels of serum proteins. This syndrome--more accurately described as 'cachexia'--manifests as growth failure in children with uremia. Acidosis and inflammation are important causes of uremic cachexia but the underlying molecular mechanism is not well understood. Concentrations of circulating cytokines, such as leptin, tumor necrosis factor-alpha, interleukin-1, and interleukin-6, are elevated in patients with end-stage renal disease and correlate with the degree of cachexia in these individuals. Other energy-modulating hormones such as ghrelin, and adipokines such as adiponectin and resistin, are also perturbed in uremia and could contribute to nutritional abnormalities. We recently showed that elevated levels of circulating cytokines might be an important contributor to uremia-associated cachexia via signaling through the central melanocortin system. Small-molecule melanocortin antagonists, which are biologically active when administered orally or intraperitoneally, are now available and have been used successfully to ameliorate experimental cachexia. These findings could form the basis of a novel therapeutic strategy for uremic cachexia.
- 1 August 2006
- Published by Elsevier in Kidney International
- Vol. 70 (3) , 410-412
Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation
- 1 August 2006
- Published by Elsevier in Kidney International
- Vol. 70 (3) , 410-412
Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation
- 1 April 2006
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 18 (2) , 148-152
Pathogenesis of urinary tract infection: an update
Urinary tract infection is the second most common bacterial infection in children. It may cause renal scarring leading to secondary hypertension and chronic kidney disease. Recent information has greatly improved our understanding of the pathogenesis of urinary tract infection and renal scarring. Urothelium, an anatomical barrier for innate immune responses, expresses toll-like receptors with the capacity to recognize pathogen-associated molecular patterns. Engagement of toll-like receptors can lead to uroepithelial cell activation and production of inflammatory mediators. These include complement proteins, other bactericidal peptides, cytokines, chemokines, defensins and adhesion molecules. The resulting inflammatory infiltrate serves to aid bacterial clearance but can also lead to renal damage. Furthermore, interactions between urinary proteins, such as Tamm-Horsfall protein, and TLR-4 add to the complexity of this defense system. Interindividual variability in cellular response may in part be responsible for variable clinical outcomes. Polymorphisms in a number of candidate genes in this host defense mechanism may be involved in determining those patients who are susceptible to recurrent infections and renal scarring following urinary tract infection. Further understanding of the basic molecular mechanisms of urinary tract infection and translating these bench data to the bedside holds the promise of improving diagnosis and therapeutic strategies of treating urinary tract infection and preventing recurrence and renal scarring.
- 1 April 2006
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 18 (2) , 148-152
Pathogenesis of urinary tract infection: an update
Urinary tract infection is the second most common bacterial infection in children. It may cause renal scarring leading to secondary hypertension and chronic kidney disease. Recent information has greatly improved our understanding of the pathogenesis of urinary tract infection and renal scarring. Urothelium, an anatomical barrier for innate immune responses, expresses toll-like receptors with the capacity to recognize pathogen-associated molecular patterns. Engagement of toll-like receptors can lead to uroepithelial cell activation and production of inflammatory mediators. These include complement proteins, other bactericidal peptides, cytokines, chemokines, defensins and adhesion molecules. The resulting inflammatory infiltrate serves to aid bacterial clearance but can also lead to renal damage. Furthermore, interactions between urinary proteins, such as Tamm-Horsfall protein, and TLR-4 add to the complexity of this defense system. Interindividual variability in cellular response may in part be responsible for variable clinical outcomes. Polymorphisms in a number of candidate genes in this host defense mechanism may be involved in determining those patients who are susceptible to recurrent infections and renal scarring following urinary tract infection. Further understanding of the basic molecular mechanisms of urinary tract infection and translating these bench data to the bedside holds the promise of improving diagnosis and therapeutic strategies of treating urinary tract infection and preventing recurrence and renal scarring.